Skip to content

Myriad Genetics MYGN Impairment Charges

Impairment Charges at other companies

Guardant Health logo
Guardant HealthGH
$0-100%
GeneDx Holdings logo
GeneDx HoldingsWGS
$31.29M
Azenta logo
AzentaAZTA
$149.08M

Other financials

Income statement

See full
Revenue$200.4M+2.3%
Gross profit$137.6M+2.5%
Operating income-$30.7M-5.9%
Net income-$34.1M-34,000%
EPS (diluted)-$0.36

Balance sheet

See full
Cash & equivalents$126.0M+24.8%
Total debt$211.5M+34.2%
Total equity$337.4M-52.1%
Total assets$673.7M-33.0%

Cash flow

See full
Operating cash flow-$15.7M+3.7%
CapEx$18.8M+181%
Free cash flow-$19.7M+65.1%

Valuation

See full
Market cap$512.85M+13.1%
Enterprise value$598.35M+17.3%
P/S0.6×+0.1×

Profitability

See full
Gross margin70%0.0pp
Operating margin-46.9%-88.3pp
Net margin-48.2%-72.9pp
FCF margin-17%

Returns & leverage

See full
Return on equity-76.7%-98.4pp
Debt / equity0.6×+0.4×
Current ratio2.4×+0.5×

Where this comes from

Reported directly by Myriad Genetics in its filing.

Tagged under the XBRL concept us-gaap:AssetImpairmentCharges.

The official record: Myriad Genetics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Myriad Genetics's impairment charges.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Myriad Genetics's impairment charges?
Myriad Genetics (MYGN) reported impairment charges of $5.4M in Q1 2026.
What is the long-term trend for Myriad Genetics's impairment charges?
Over 4 years (2021 to 2025), Myriad Genetics's impairment charges has grown at a 265.0% compound annual growth rate (CAGR), from $1.8M to $319.4M.
What does impairment charges mean?
Non-cash asset impairment charges added back in the operating cash flow reconciliation since they don't represent cash outflows.